Prospects for the development of pre-mortem laboratory diagnostic tests for Creutzfeldt-Jakob disease

Reviews in Medical Virology

Volumn 14, Issue 6, 2004, Pages 345-361

  Dabaghian, Reza H ^a   Mortimer, Philip P ^a   Clewley, Jonathan P ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APTAMER; ERYTHROID DIFFERENTIATION RELATED FACTOR; MESSENGER RNA; METHIONINE; MONOCLONAL ANTIBODY; PLASMINOGEN; POLYCLONAL ANTIBODY; PRION PROTEIN; PROTEIN 14 3 3; UNCLASSIFIED DRUG;

ANIMAL MODEL; BIOASSAY; BLOOD TRANSFUSION; BODY FLUID; BRAIN DISEASE; CELL CULTURE; CENTRAL NERVOUS SYSTEM INFECTION; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; ERYTHROID CELL; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUOROIMMUNOASSAY; FOURIER TRANSFORMATION; GEL ELECTROPHORESIS; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; INFRARED SPECTROSCOPY; LABORATORY DIAGNOSIS; LABORATORY TEST; LIGAND BINDING; MARKER GENE; MOUSE; NEUROBLASTOMA CELL; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PRION DISEASE; PROTEIN STRUCTURE; REVIEW; WESTERN BLOTTING;

ANIMALS; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; MODELS, MOLECULAR; PRPC PROTEINS; PRPSC PROTEINS;

EID: 8444228139     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.450     Document Type: Review

References (161)

1. Kaneko K, Zulianello L, Scott M, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 1997; 94: 10069-10074.
2. Lee KS, Linden R, Prado MA, Brentani RR, Martins VR. Towards cellular receptors for prions. Rev Med Virol 2003; 13: 399-408.
3. Sigurdson CJ, Williams ES, Miller MW, Spraker TR, O'Rourke KI, Hoover EA. Oral transmission and early lymphoid tropism of chronic wasting disease PrPres in mule deer fawns (Odocoileus hemionus). J Gen Virol 1999; 80: 2757-2764.
4. Sigurdson CJ, Miller MW. Other animal prion diseases. Br Med Bull 2003; 66: 199-212.
5. Detwiler LA, Baylis M. The epidemiology of scrapie. Rev Sci Tech 2003; 22: 121-143.
6. Wilesmith JW, Wells GA, Cranwell MP, Ryan JB. Bovine spongiform encephalopathy: epidemiological studies. Vet Rec 1988; 123: 638-644.
7. Wilesmith JW, Ryan JB, Hueston WD. Bovine spongiform encephalopathy: case-control studies of calf feeding practices and meat and bonemeal inclusion in proprietary concentrates. Res Vet Sci 1992; 52: 325-331.
8. Prusiner SB. Detecting mad cow disease. Sci Am 2004; 291: 60-67.
9. Bostock C. The nature of TSEs. Microbiol Today 2000; 27: 164-166.
10. Brown P, Will RG, Bradley R, Asher DM, Detwiler LA. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis 2001; 7: 6-16.
11. Caughey B. Interactions between prion protein isoforms: the kiss of death? Trends Biochem Sci 2001; 26: 235-242.
12. Chesebro B. Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 2003; 66: 1-20.
13. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66: 255-265.
14. Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004; 116: 313-327.
15. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61.
16. Brown P, Cervenákova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001; 137: 5-13.
17. Bennion BJ, Daggett V. Protein confirmation and diagnostic tests: the prion protein. Clin Chem 2002; 48: 2105-2114.
18. Hoots WK, Abrams C, Tankersleydagger D. The impact of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease on plasma safety. Transfus Med Rev 2001; 15: 45-59.
19. MacGregor I. Prion protein and developments in its detection. Transfus Med 2001; 11: 3-14.
20. Ingrosso L, Vetrugno V, Cardone F, Pocchiari M. Molecular diagnostics of transmissible spongiform encephalopathies. Trends Mol Med 2002; 8: 273-280.
21. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-233.
22. Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126: 1333-1346.
23. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977; 197: 943-960.
24. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95: 13363-13383.
25. Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779-788.
26. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-421.
27. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897-2905.
28. Baier M, Norley S, Schultz J, Burwinkel M, Schwarz A, Riemer C. Prion diseases: infectious and lethal doses following oral challenge. J Gen Virol 2003; 84: 1927-1929.
29. Andrews NJ, Farrington CP, Ward HJ, et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 2003; 361: 751-752.
30. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003; 3: 4.
31. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-739.
32. Anonymous. The National Anonymous Tonsil Archive: a resource for Creutzfeldt-Jakob disease studies. CDR Weekly 2003; 13: 3-4.
33. King C-Y, Diaz-Avalos R. Protein-only transmission of three yeast prion strains. Nature 2004; 428: 319-323.
34. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Conformational variations in an infectious protein determine prion strain differences. Nature 2004; 428: 323-327.
35. Dickinson AG, Outram GW. Genetic aspects of unconventional virus infections: the basis of the virino hypothesis. Ciba Found Symp 1988; 135: 63-83.
36. Diener TO, McKinley MP, Prusiner SB. Viroids and prions. Proc Natl Acad Sci USA 1982; 79: 5220-5224.
37. Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003; 425: 717-720.
38. Bruce ME. TSE strain variation. Br Med Bull 2003; 66: 99-108.
39. Somerville RA. TSE agent strains and PrP: reconciling structure and function. Trends Biochem Sci 2002; 27: 606-612.
40. Caughey B, Raymond GJ, Bessen RA. Strain-dependent differences in beta-sheet conformations of abnormal prion protein. J Biol Chem 1998; 273: 32230-32235.
41. Safar J, Wille H, Itri V, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 1998; 4: 1157-1165.
42. Rudd PM, Merry AH, Wormald MR, Dwek RA. Glycosylation and prion protein. Curr Opin Struc Biol 2002; 12: 578-586.
43. Vorberg I, Priola SA. Molecular basis of scrapie strain glycoform variation. J Biol Chem 2002; 277: 36775-36781.
44. Atkinson PH. Glycosylation of prion strains in transmissible spongiform encephalopathies. Aust Vet J 2004; 82: 292-299.
45. Asante EA, Linehan JM, Desbruslais M, et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 2002; 21: 6358-6366.
46. Brown P, Meyer R, Cardone F, Pocchiari M. Ultra-high-pressure inactivation of prion infectivity in processed meat: a practical method to prevent human infection. Proc Natl Acad Sci USA 2003; 100: 6093-6097.
47. Wadsworth JD, Hill AF, Beck JA, Collinge J. Molecular and clinical classification of human prion disease. Br Med Bull 2003; 66: 241-254.
48. Collinge J, Sidle KCL, Meads J, Ironside J, Hills AF. Molecular analysis of prion strain variation and aetiology of 'new variant' CJD. Nature 1996; 383: 685-690.
49. Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171-180.
50. Head MW, Bunn TJR, Bishop MT, et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann Neurol 2004; 55: 851-859.
51. Notari S, Capellari S, Giese A, et al. Effects of different experimental conditions on the PrPSc core generated by protease digestion: implications for strain typing and molecular classification of CJD. J Biol Chem 2004; 279: 16797-16804.
52. Mouillet-Richard S, Ermonval M, Chebassier C, et al. Signal transduction through prion protein. Science 2000; 289: 1925-1928.
53. Brown DR, Qin K, Herms JW, et al. The cellular prion protein binds copper in vivo. Nature 1997; 390: 684-687.
54. Brown DR, Besinger A. Prion protein expression and superoxide dismutase activity. Biochem J 1998; 334: 423-429.
55. Sakudo A, Lee DC, Saeki K, et al. Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Biochem Biophys Res Commun 2003; 308: 660-667.
56. Lopez Garcia F, Zahn R, Riek R, Wuthrich K. NMR structure of the bovine prion protein. Proc Natl Acad Sci USA 2000; 97: 8334-8339.
57. Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003; 66: 21-33.
58. Cappai R, Collins S. Structural biology of prions. In Prions: A Challenge for Science, Medicine and the Public Health System, Rabenau HF, Cinatl J, Doerr HW (eds): Karger: Basel, 2004; 14-32.
59. Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its protein isoform. J Biol Chem 1997; 272: 6324-6331.
60. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 1991; 30: 7672-7680.
61. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed {beta}-helices into trimers. Proc Natl Acad Sci USA 2004; 101: 8342-8347.
62. Kajava AV, Baxa U, Wickner RB, Steven AC. A model for Ure2p prion filaments and other amyloids: The parallel superpleated {beta}-structure. Proc Natl Acad Sci USA 2004; 101: 7885-7890.
63. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Eng J Med 2003; 349: 583-596.
64. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002; 277: 21140-21148.
65. Morel N, Simon S, Frobert Y, et al. Selective and efficient immunoprecipitation of the disease-associated form of the prion protein can be mediated by non-specific interactions between monoclonal antibodies and scrapie-associated fibrils. J Biol Chem 2004; 279: 30143-30149.
66. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 1983; 35: 57-62.
67. Meyer RK, McKinley MP, Bowman KA, Braunfeld MB, Barry RA, Prusiner SB. Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci USA 1986; 83: 2310-2314.
68. Groschup MH, Beekes M, McBride PA, Hardt M, Hainfellner JA, Budka H. Deposition of disease-associated prion protein involves the peripheral nervous system in experimental scrapie. Acta Neuropathol (Berl) 1999; 98: 453-457.
69. Maignien T, Lasmezas CI, Beringue V, Dormont D, Deslys JP. Pathogenesis of the oral route of infection of mice with scrapie and bovine spongiform encephalopathy agents. J Gen Virol 1999; 80: 3035-3042.
70. Bosque PJ, Ryou C, Telling G, et al. Prions in skeletal muscle. Proc Natl Acad Sci USA 2002; 99: 3812-3817.
71. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 349: 1812-1820.
72. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
73. Hilton DA, Ghani AC, Conyers L, et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br Med J 2002; 325: 633-634.
74. Beekes M, Baldauf E, Diringer H. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. J Gen Virol 1996; 77: 1925-1934.
75. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-189.
76. van Keulen LJ, Schreuder BE, Vromans ME, Langeveld JP, Smits MA. Pathogenesis of natural scrapie in sheep. Arch Virol Suppl 2000; 16: 57-71.
77. McBride PA, Eikelenboom P, Kraal G, Fraser H, Bruce ME. PrP protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. J Pathol 1992; 168: 413-418.
78. Kitamoto T, Mohri S, Ironside JW, et al. Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions. Biochem Biophys Res Commun 2002; 294: 280-286.
79. Kitamoto T, Muramoto T, Mohri S, Doh-Ura K, Tateishi J. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J Virol 1991; 65: 6292-6295.
80. Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001; 7: 485-487.
81. Cardone F, Pocchiari M. A role for complement in transmissible spongiform encephalopathies. Nat Med 2001; 7: 410-411.
82. Klein MA, Kaeser PS, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488-492.
83. Borchelt DR, Koliatsos VE, Guarnieri M, Pardo CA, Sisodia SS, Price DL. Rapid anterograde axonal transport of the cellular prion glycoprotein in the peripheral and central nervous systems. J Biol Chem 1994; 269: 14711-14714.
84. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302: 871-874.
85. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, Collinge J. Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci USA 2000; 97: 10248-10253.
86. Bons N, Lehmann S, Mestre-Frances N, Dormont D, Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion 2002; 42: 513-516.
87. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001; 276: 31479-31482.
88. Schmerr MJ, Jenny AL, Bulgin MS, et al. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A 1999; 853: 207-214.
89. Will RG, Zeidler M, Stewart GE, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000; 47: 575-582.
90. Henry C, Knight R. Clinical features of variant Creutzfeldt-Jakob disease. Rev Med Virol 2002; 12: 143-150.
91. Vargas ME, Kupersmith MJ, Savino PJ, Petito F, Frohman LP, Warren FA. Homonymous field defect as the first manifestation of Creutzfeldt-Jakob disease. Am J Ophthalmol 1995; 119: 497-504.
92. Katz BJ, Warner JE, Digre KB, Creel DJ. Selective loss of the electroretinogram B-wave in a patient with Creutzfeldt-Jakob disease. J Neuroophthalmol 2000; 20: 116-118.
93. Itoh Y, Amano T, Shimizu T, Hashimoto J, Kubo A, Fukuuchi Y. Single-photon emission computed tomography image of benzodiazepine receptors in a patient with Creutzfeldt-Jakob disease. Intern Med 1998; 37: 896-900.
94. Kubler E, Oesch B, Raeber AJ. Diagnosis of prion diseases. Br Med Bull 2003; 66: 267-279.
95. Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS 2002; 110: 79-87.
96. Schreuder BE, van Keulen LJ, Vromans ME, Langeveld JP, Smits MA. Preclinical test for prion diseases. Nature 1996; 381: 563.
97. Wild MA, Spraker TR, Sigurdson CJ, O'Rourke KI, Miller MW. Preclinical diagnosis of chronic wasting disease in captive mule deer (Odocoileus hemionus) and white-tailed deer (Odocoileus virginianus) using tonsillar biopsy. J Gen Virol 2002; 83: 2629-2634.
98. Schreuder BE, Somerville RA. Bovine spongiform encephalopathy in sheep? Rev Sci Tech 2003; 22: 103-120.
99. Hilton DA, Fathers E, Edwards P, Ironside JW, Zaijcek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-704.
100. Ironside JW, Hilton DA, Ghani A, et al. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet 2000; 355: 1693-1694.
101. Glatzel M, Ott PM, Linder T, et al. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol 2003; 2: 757-763.
102. Raeber AJ, Montrasio F, Hegyi I, et al. Studies on prion replication in spleen. Dev Immunol 2001; 8: 291-304.
103. Race R, Fadness L, Chesebro B. Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol 1987; 68: 1391-1399.
104. Bosque PJ, Prusiner SB. Cultured cell sublines highly susceptible to prion infection. J Virol 2000; 74: 4377-4386.
105. Klohn P-C, Stoltze L, Flechsig E, Enari M, Weissmann C. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci USA 2003; 100: 11666-11671.
106. Parchi P, Capellari S, Chen SG. Typing prion isoforms. Nature 1997; 386: 232-233.
107. Wads worth JD, Hill AF, Joiner S, Jackson GS, Clarke AR, Collinge J. Strain-specific prion-protein conformation determined by metal ions. Nat Cell Biol 1999; 1: 55-59.
108. Race RE, Raines A, Baron TGM, Miller MW, Jenny A, Williams ES. Comparison of abnormal prion protein glycoform patterns from transmissible spongiform encephalopathy agent-infected deer, elk, sheep, and cattle. J Virol 2002; 76: 12365-12368.
109. Grassi J. Pre-clinical diagnosis of transmissible spongiform encephalopathies using rapid tests. Transfus Clin Biol 2003; 10: 19-22.
110. Grassi J, Creminon C, Frobert Y, et al. Specific determination of the proteinase K-resistant form of the prion protein using two-site immunometric assays. Application to the post-mortem diagnosis of BSE. In Prion Diseases Diagnosis and Pathogenesis, Groschup MH, Kretzschmar HA (eds). Springer; Wien/New York, 2000; 197-205.
111. Moynagh J, Schimmel H, Kramer GN. The evaluation of tests for the diagnosis of transmissible spongiform encephalopathy in bovines. The European Commission, http://europa.eu.int/comm/food/fs/bse/bse12_en.pdf. 1999. [1 June, 2004].
112. Moynagh J, Schimmel H. Tests for BSE evaluated. Nature 1999; 400: 105.
113. Oesch B, Doherr M, Heim D, et al. Application of prionics western blotting procedure to screen for BSE in cattle regularly slaughtered at Swiss abattoirs. In Prion Diseases Diagnosis and Pathogenesis, Groschup MH, Kretzschmar HA (eds). Springer: Wien/New York, 2000; 189-195.
114. Schaller O, Fatzer R, Stack M, et al. Validation of a western immunoblotting procedure for bovine PrP(Sc) detection and its use as a rapid surveillance method for the diagnosis of bovine spongiform encephalopathy (BSE). Acta Neuropathol (Berl) 1999; 98: 437-443.
115. Oesch B, Doherr M, Heim D, et al. Application of prionics western blotting procedure to screen for BSE in cattle regularly slaughtered at Swiss abattoirs. Arch Virol Suppl 2000; 16: 189-195.
116. Biffiger K, Zwald D, Kaufmann L, et al. Validation of a luminescence immunoassay for the detection of PrP(Sc) in brain homogenate. J Virol Meth 2002; 101: 79-84.
117. Safar JG, Scott M, Monaghan J, et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol 2002; 20: 1147-1150.
118. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Groner A, Vey M. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 2003; 84: 1921-1925.
119. Barnard G, Helmick B, Madden S, Gilbourne C, Patel R. The measurement of prion protein in bovine brain tissue using differential extraction and DELFIA as a diagnostic test for BSE. Luminescence 2000; 15: 357-362.
120. MacGregor I, Hope J, Barnard G, et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999; 77: 88-96.
121. Lane A, Stanley CJ, Dealler S, Wilson SM. Polymeric ligands with specificity for aggregated prion proteins. Clin Chem 2003; 49: 1774-1775.
122. Kascsak RJ, Rubenstein R, Merz PA, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987; 61: 3688-3693.
123. Korth C, Stierli B, Streit P, et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997; 390: 74-77.
124. Serbec VC, Bresjanac M, Popovic M, et al. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue. J Biol Chem 2004; 279: 3694-3698.
125. Paramithiotis E, Pinard M, Lawton T, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9: 893-899.
126. Paramithiotis E, Pinard M, Lawton T, et al. Properties of a disease-specific prion probe. Nat Med 2004; 10: 11-12.
127. Gorochov G, Deslys J-P. Properties of a disease-specific prion probe. Nat Med 2004; 10: 11.
128. Jackman R, Schmerr MJ. Analysis of the performance of antibody capture methods using fluorescent peptides with capillary zone electrophoresis with laser-induced fluorescence. Electrophoresis 2003; 24: 892-896.
129. Brown P. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. Br Med J 2001; 322: 841-844.
130. Giese A, Bieschke J, Eigen M, Kretzschmar HA. Putting prions into focus: application of single molecule detection to the diagnosis of prion diseases. Arch Virol Suppl 2000; 16: 161-171.
131. Bieschke J, Giese A, Schulz-Schaeffer W, et al. Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. Proc Natl Acad Sci USA 2000; 97: 5468-5473.
132. Jenison RD, Gill SC, Pardi A, Polisky B. High-resolution molecular discrimination by RNA. Science 1994; 263: 1425-1429.
133. Weiss S, Proske D, Neumann M, et al. RNA aptamers specifically interact with the prion protein PrP. J Virol 1997; 71: 8790-8797.
134. Kocisko DA, Come JH, Priola SA, et al. Cell-free formation of protease-resistant prion protein. Nature 1994; 370: 471-474.
135. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury PT, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 1995; 375: 698-700.
136. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT Jr, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci USA 1995; 92: 3923-3927.
137. Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci USA 2000; 97: 5836-5841.
138. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810-813.
139. Lucassen R, Nishina K, Supattapone S. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 2003; 42: 4127-4135.
140. Jackson GS, Hosszu LL, Power A, et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 1999; 283: 1935-1937.
141. Hill A, Antoniou M, Collinge J. Protease-resistant prion protein produced in vitro lacks detectable infectivity. J Gen Virol 1999; 80: 11-14.
142. Tzivion G, Avruch J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002; 277: 3061-3064.
143. Berg D, Holzmann C, Riess 0.14-3-3 proteins in the nervous system. Nat Rev Neourosci 2003; 4: 752-762.
144. Aitken A, Jones D, Soneji Y, Howell S. 14-3-3 proteins: biological function and domain structure. Biochem Soc Trans 1995; 23: 605-611.
145. Hsich G, Kenney K, Gibbs CJ Jr, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Eng J Med 1996; 335: 924-930.
146. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000; 48: 395-398.
147. Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Trans 2002; 30: 382-386.
148. Zerr I, Bodemer M, Otto M, et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 1996; 348: 846-849.
149. Duguid J, Trzepacz C. Major compatibility complex genes have an increased brain expression after scrapie infection. Proc Natl Acad Sci USA 1993; 90: 114-117.
150. Riemer C, Queck I, Simon D, Kurth R, Baier M. Identification of upregulated genes in scrapie-infected brain tissue. J Virol 2000; 74: 10245-10248.
151. Miele G, Manson J, Clinton M. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat Med 2001; 7: 361-364.
152. Wang D, Li Y, Shen B. A novel erythroid differentiation related gene EDRF1 upregulating globin gene expression in HEL cells. Chin Med J (Engl) 2002; 115: 1701-1705.
153. Clock B, Winter M, Rennhofer SO, et al. Transcript level of erythroid differentiation-related factor, a candidate surrogate marker for transmissible spongiform encephalopathy diseases in blood, shows a broad range of variation in healthy individuals. Transfusion 2003; 43: 1706-1710.
154. Schmitt J, Beekes M, Brauer A, Udelhoven T, Lasch P, Naumann D. Identification of scrapie infection from blood serum by Fourier transform infrared spectroscopy. Anal Chem 2002; 74: 3865-3868.
155. Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408: 479-483.
156. Shaked Y, Engelstein R, Gabizon R. The binding of prion proteins to serum components is affected by detergent extraction conditions. J Neurochem 2002; 82: 1-5.
157. Mead S, Stumpf MPH, Whitfield J, et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science 2003; 300: 640-643.
158. Petraroli R, Vaccari G, Pocchiari M. A rapid and efficient method for the detection of point mutations of the human prion protein gene (PRNP) by direct sequencing. J Neurosci Meth 2000; 99: 59-63.
159. Teupser D, Heino N, Wilfert W, Thiery J. Rapid detection of the prion protein M129V polymorphism with the LightCycler. J Neurosci Meth 2002; 115: 93-96.
160. Chesebro B. BSE and prions: uncertainties about the agent. Science 1998; 279: 42-43.
161. Wille H, Michelitsch MD, Guenebaut V, et al. Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci USA 2002; 99: 3563-3568.